Italia markets open in 2 hours 14 minutes

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Prezzo differito. Valuta in JPY.
Aggiungi a watchlist
4.373,00-16,00 (-0,36%)
In data: 02:26PM JST. Mercato aperto.
Schermo intero
Chiusura precedente4.389,00
Denaro4.372,00 x 0
Lettera4.374,00 x 0
Min-Max giorno4.367,00 - 4.403,00
Intervallo di 52 settimane3.900,00 - 4.873,00
Media Volume4.399.032
Beta (5 anni mensile)0,54
Rapporto PE (ttm)38,92
EPS (ttm)112,36
Prossima data utili09 mag 2024
Rendimento e dividendo (futuro)188,00 (4,28%)
Data ex dividendo28 mar 2024
Stima target 1A4.745,30
  • GlobeNewswire

    HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

    — Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:​HCM, HKEX:​13) (“HUTCHMED”) today announced that Takeda (TSE:4502/​NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously

  • GlobeNewswire

    HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

    — Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) and Takeda (TSE:4502, NYSE:TAK) today announced that results

  • GlobeNewswire

    Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

    WESTWOOD, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Corza Medical announced today that it has entered into a definitive agreement with a subsidiary of Takeda Pharmaceuticals Company (TSE:4502/NYSE:TAK) (“Takeda”) to acquire the TachoSil manufacturing operations in Linz, Austria. Corza Medical had previously acquired the commercial product rights for TachoSil, a best-in-class surgical patch trusted by medical professionals worldwide, in January 2021. Corza Medical shares Takeda’s commitment to pa